Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1-700 mg) of BI 638683 Powder in Bottle (PiB) in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2015
At a glance
- Drugs BI 638683 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Biomarker
- Sponsors Boehringer Ingelheim
- 15 Dec 2010 Trial status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Sep 2010 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 20 Sep 2010 Actual initiation date added to 1 Sep 2010 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History